Média

Onxeo successfully raises €15 Million with US and European investors

Offering upsized in response to investor demand   Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced a capital raise for gross proceeds of approximately…read more →

Onxeo launches a capital increase by means of an accelerated book-build offering

Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the launch of a capital increase directed at certain institutional investors located in France and internationally….read more →

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 10th unanimous recommendation from the Data Safety Monitoring Board (DSMB), to continue without modification…read more →

Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma

USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032 Paris (France), May 10, 2017 – 6.30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology,…read more →

Annual General Meeting of April 26, 2017

All ordinary resolutions approved Two new independent directors appointed Renewal of the terms of office of Mrs Judith Greciet, CEO, and Financière de la Montagne Notice for new Extraordinary General Meeting on May 24, 2017 Paris, April 26, 2017 – 8.45 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs…read more →

Onxeo: Q1 2017 financial information and business update

    Revenues up 55% to €1.2 million     Cash position of €21.7 million at March 31, 2017     All strategic assets are progressing according to development plans   Paris, April 26, 2017 – 6.30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in…read more →

Publication of 2016 Registration Document

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2016 Registration Document. The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Paris, April 24, 2017 – 18 :30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL is a…read more →

Onxeo receives the EnterNext Tech 40 Label

Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the various Euronext markets in Europe Paris, April 20, 2017 – 8:30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology,…read more →

Combined General Meeting on April 26, 2017

Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on Wednesday,…read more →

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today the presentation of data from three studies supporting the company’s primary drug candidates in…read more →

Full-year 2016 Results and Outlook for 2017

Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, a first-in-class candidate in the new area of preventing tumor cells from repairing their DNA Enrolment for the phase III Livatag® study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Cash and cash equivalents of…read more →

Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development

Françoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer to Lead Clinical Development and Operations, Medical and Regulatory Affairs Paris (France), March 1, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment…read more →

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark…read more →